Oxford Biomedica (LON:OXB) Reaches New 52-Week High - Time to Buy?

Key Points

• Oxford Biomedica's shares reached a new 52-week high at GBX 512 ($6.89) amid increased trading activity, showing significant investor interest.
• Analysts have mixed ratings on the stock, with JPMorgan reducing their price target to GBX 400 and Peel Hunt maintaining a "buy" rating with a target of GBX 451.
• Recent insider transactions included Roch Doliveux acquiring 67,000 shares at GBX 450, reflecting confidence from company executives in the stock's future performance.

Shares of Oxford Biomedica plc (LON:OXB - Get Free Report) reached a new 52-week high during trading on Thursday . The company traded as high as GBX 512 ($6.89) and last traded at GBX 507.05 ($6.82), with a volume of 130906 shares. The stock had previously closed at GBX 505 ($6.79).

Analysts Set New Price Targets

OXB has been the topic of a number of research analyst reports. JPMorgan Chase & Co. reduced their price target on shares of Oxford Biomedica from GBX 490 to GBX 400 and set a "neutral" rating on the stock in a research note on Tuesday, July 15th. Peel Hunt restated a "buy" rating and issued a GBX 451 target price on shares of Oxford Biomedica in a research report on Friday, August 1st. Finally, Royal Bank Of Canada upped their price target on shares of Oxford Biomedica from GBX 800 to GBX 930 and gave the stock an "outperform" rating in a report on Tuesday. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, Oxford Biomedica currently has a consensus rating of "Moderate Buy" and an average price target of GBX 540.25.

Oxford Biomedica Price Performance

The company has a debt-to-equity ratio of 166.48, a quick ratio of 1.67 and a current ratio of 2.35. The business has a 50 day moving average price of GBX 395.39 and a 200-day moving average price of GBX 340.61. The company has a market capitalization of £591.03 million, a price-to-earnings ratio of -4.13 and a beta of 1.09.

Insider Buying and Selling at Oxford Biomedica

In other Oxford Biomedica news, insider Roch Doliveux purchased 67,000 shares of the business's stock in a transaction on Friday, August 15th. The shares were purchased at an average cost of GBX 450 per share, for a total transaction of £301,500. Also, insider Heather Preston acquired 11,389 shares of Oxford Biomedica stock in a transaction dated Tuesday, June 17th. The shares were bought at an average cost of GBX 324 per share, with a total value of £36,900.36. Insiders own 21.17% of the company's stock.

Oxford Biomedica Company Profile

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.